Navigation Links
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
Date:2/20/2008

ation, the basis of Addrenex's drug development efforts.

"We credit our rapid success in developing viable drugs and building partnerships to our nimble, fast-paced business model and outside-the-box thinking," Khayrallah said. "We stay sharply focused on the major milestones that must be accomplished, and we don't allow perceived impediments to hamper our progress."

Addrenex's goal is to develop a diverse pipeline of products aimed at regulating the adrenergic system, a vast and varied regulator of multiple bodily processes. The alpha-2 adrenergic receptors in particular have been implicated in a wide variety of medical conditions, including hypertension, ADHD, menopausal flushing, migraine, sleep disturbances, aggression, pain and addiction.

Few drugs on the market are known to target the alpha-2 adrenergic receptors; hence, Addrenex is seeking to fill a void in this pharmaceutical niche, Khayrallah said.

About Addrenex Pharmaceuticals, Inc.

Addrenex Pharmaceuticals is a focused, specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, North Carolina, on the edge of Research Triangle Park. The company was formed in 2006 by a practicing physician and a drug development expert with the mission to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraine, and post-menopausal symptoms. Addrenex will use the knowledge and experience gained from developing CloniBID and Clonicel as the foundation for additional discovery and development in the area of adrenergic regulation.


'/>"/>
SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... -- Bina Technologies, Inc. (Bina, Redwood City, ... been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).  ... that provides a big data platform for centralized management ... the academic and translational research markets.  Bina will be ... to focus on development of their innovative genomic analysis ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service ... detailed assessment on technological advancements and market for ... 1. The Smart Fabrics market is expected ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... , , SOUTH SAN ... SNSS ) reported today that it received a letter, dated September ... NASDAQ Stock Market notifying Sunesis that it does not comply with ... NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2). The ...
... , SAN DIEGO, Sept. 18, 2009 ... today that the company is scheduled to present at the UBS ... Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel ... Officer, is scheduled to provide an overview of the company, including ...
... PRINCETON, N.J., Sept. 18 Covance Inc. (NYSE: ... Global Life Sciences Conference on Monday, September 21, 2009 at 10:00 ... presentation at www.covance.com . In order to ... early. , , Covance, with headquarters in Princeton, ...
Cached Biology Technology:Sunesis Pharmaceuticals Receives NASDAQ Notification 2Sunesis Pharmaceuticals Receives NASDAQ Notification 3Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 2Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... hadrosaur (duck-billed) dinosaur the oldest duck-billed dinosaur known ... who expect the discovery to shed new light on ... gagslarsoni , the name given to the new dinosaur, ... to later duck-billed relatives. Acristavus means "non-crested ...
... PASADENA, Calif.Artificial intelligence has been the inspiration for countless ... countless scientists and engineers. Researchers at the California Institute ... toward creating artificial intelligencenot in a robot or a ... are the first to have made an artificial neural ...
... SALT LAKE CITY A team of researchers from the ... mouse model of focal dermal hypoplasia, a rare human birth ... This animal model not only provides insight into studying the ... novel way to study a signaling pathway that is crucial ...
Cached Biology News:New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality 2Caltech researchers create the first artificial neural network out of DNA 2Caltech researchers create the first artificial neural network out of DNA 3Caltech researchers create the first artificial neural network out of DNA 4Animal model sheds light on rare genetic disorder, signaling pathway 2
Human Cell Line Slides...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
Biology Products: